Does the media favor PTCT or UTHR?

In the previous week, United Therapeutics had 8 more articles in the media than PTC Therapeutics. MarketBeat recorded 23 mentions for United Therapeutics and 15 mentions for PTC Therapeutics. United Therapeutics' average media sentiment score of 0.65 beat PTC Therapeutics' score of 0.60 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 13 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PTCT or GMAB more profitable?

Genmab A/S has a net margin of 19.08% compared to PTC Therapeutics' net margin of -3.80%. Genmab A/S's return on equity of 14.89% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -3.80% -362.45% -1.32% Genmab A/S 19.08% 14.89% 7.73%

Does the media favor PTCT or GMAB?

In the previous week, PTC Therapeutics had 3 more articles in the media than Genmab A/S. MarketBeat recorded 15 mentions for PTC Therapeutics and 12 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.64 beat PTC Therapeutics' score of 0.60 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASND or PTCT?

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than PTC Therapeutics. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 15 mentions for PTC Therapeutics. Ascendis Pharma A/S's average media sentiment score of 0.68 beat PTC Therapeutics' score of 0.60 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 7 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTCT or BBIO?

In the previous week, PTC Therapeutics had 7 more articles in the media than BridgeBio Pharma. MarketBeat recorded 15 mentions for PTC Therapeutics and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat PTC Therapeutics' score of 0.60 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SMMT or PTCT?

In the previous week, PTC Therapeutics had 8 more articles in the media than Summit Therapeutics. MarketBeat recorded 15 mentions for PTC Therapeutics and 7 mentions for Summit Therapeutics. PTC Therapeutics' average media sentiment score of 0.60 beat Summit Therapeutics' score of 0.20 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral PTC Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PTC Therapeutics (PTCT) Competitors

$65.37 -2.63 (-3.87%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$65.36 -0.01 (-0.02%)

As of 09/18/2026 07:46 PM Eastern

Compare

PTCT vs. UTHR, GMAB, ASND, BBIO, and SMMT

Should you buy PTC Therapeutics stock or one of its competitors? PTC Therapeutics's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PTC Therapeutics compare to United Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

United Therapeutics has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.01B	5.41	$682.64M	-$0.58	N/A
United Therapeutics	$3.18B	6.67	$1.33B	$27.95	17.70

In the previous week, United Therapeutics had 8 more articles in the media than PTC Therapeutics. MarketBeat recorded 23 mentions for United Therapeutics and 15 mentions for PTC Therapeutics. United Therapeutics' average media sentiment score of 0.65 beat PTC Therapeutics' score of 0.60 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	13 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.1% of United Therapeutics shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PTC Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

PTC Therapeutics currently has a consensus target price of $98.50, suggesting a potential upside of 50.68%. United Therapeutics has a consensus target price of $646.00, suggesting a potential upside of 30.60%. Given PTC Therapeutics' higher probable upside, equities analysts plainly believe PTC Therapeutics is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has a net margin of 41.56% compared to PTC Therapeutics' net margin of -3.80%. United Therapeutics' return on equity of 20.18% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
United Therapeutics	41.56%	20.18%	17.98%

Summary

United Therapeutics beats PTC Therapeutics on 15 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Genmab A/S?

PTC Therapeutics (NASDAQ:PTCT) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

PTC Therapeutics currently has a consensus target price of $98.50, indicating a potential upside of 50.68%. Genmab A/S has a consensus target price of $39.50, indicating a potential upside of 13.70%. Given PTC Therapeutics' higher probable upside, equities analysts plainly believe PTC Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Genmab A/S has a net margin of 19.08% compared to PTC Therapeutics' net margin of -3.80%. Genmab A/S's return on equity of 14.89% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
Genmab A/S	19.08%	14.89%	7.73%

7.1% of Genmab A/S shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, PTC Therapeutics had 3 more articles in the media than Genmab A/S. MarketBeat recorded 15 mentions for PTC Therapeutics and 12 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.64 beat PTC Therapeutics' score of 0.60 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.01B	5.41	$682.64M	-$0.58	N/A
Genmab A/S	$3.72B	5.83	$963M	$1.27	27.35

Summary

Genmab A/S beats PTC Therapeutics on 12 of the 16 factors compared between the two stocks.

How does PTC Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Ascendis Pharma A/S has a net margin of 70.99% compared to PTC Therapeutics' net margin of -3.80%. Ascendis Pharma A/S's return on equity of 32.54% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Ascendis Pharma A/S has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than PTC Therapeutics. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 15 mentions for PTC Therapeutics. Ascendis Pharma A/S's average media sentiment score of 0.68 beat PTC Therapeutics' score of 0.60 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	7 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has higher revenue and earnings than Ascendis Pharma A/S. PTC Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.13	-$258M	$12.89	18.36
PTC Therapeutics	$1.01B	5.41	$682.64M	-$0.58	N/A

Ascendis Pharma A/S currently has a consensus price target of $310.75, suggesting a potential upside of 31.27%. PTC Therapeutics has a consensus price target of $98.50, suggesting a potential upside of 50.68%. Given PTC Therapeutics' higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Ascendis Pharma A/S beats PTC Therapeutics on 10 of the 14 factors compared between the two stocks.

How does PTC Therapeutics compare to BridgeBio Pharma?

PTC Therapeutics (NASDAQ:PTCT) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

99.9% of BridgeBio Pharma shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PTC Therapeutics has a net margin of -3.80% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
BridgeBio Pharma	-97.03%	N/A	-61.19%

PTC Therapeutics has higher revenue and earnings than BridgeBio Pharma. PTC Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.01B	5.41	$682.64M	-$0.58	N/A
BridgeBio Pharma	$502.08M	25.94	-$724.93M	-$3.57	N/A

In the previous week, PTC Therapeutics had 7 more articles in the media than BridgeBio Pharma. MarketBeat recorded 15 mentions for PTC Therapeutics and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat PTC Therapeutics' score of 0.60 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics presently has a consensus price target of $98.50, indicating a potential upside of 50.68%. BridgeBio Pharma has a consensus price target of $102.61, indicating a potential upside of 54.05%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

PTC Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Summary

BridgeBio Pharma beats PTC Therapeutics on 10 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, PTC Therapeutics had 8 more articles in the media than Summit Therapeutics. MarketBeat recorded 15 mentions for PTC Therapeutics and 7 mentions for Summit Therapeutics. PTC Therapeutics' average media sentiment score of 0.60 beat Summit Therapeutics' score of 0.20 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
PTC Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. Summit Therapeutics' return on equity of -168.94% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Summit Therapeutics presently has a consensus price target of $25.91, suggesting a potential upside of 45.14%. PTC Therapeutics has a consensus price target of $98.50, suggesting a potential upside of 50.68%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PTC Therapeutics has higher revenue and earnings than Summit Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
PTC Therapeutics	$1.01B	5.41	$682.64M	-$0.58	N/A

Summit Therapeutics has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Summary

PTC Therapeutics beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTCT vs. The Competition

Export

Metric	PTC Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.68B	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-112.71	14.30	275.79	25.40
Price / Sales	5.41	1,415.50	695.58	114.44
Price / Cash	7.75	110.75	77.42	51.66
Price / Book	-25.54	15.45	10.46	6.33
Net Income	$682.64M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-1.04%	-1.21%	0.59%	1.12%
1 Month Performance	-11.27%	-4.42%	-2.01%	-2.67%
1 Year Performance	8.09%	37.81%	18.09%	6.01%

PTC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTCT PTC Therapeutics	3.6002 of 5 stars	$65.37 -3.9%	$98.50 +50.7%	+4.0%	$5.68B	$1.01B	N/A	991	News Coverage Analyst Downgrade Insider Trade High Trading Volume
UTHR United Therapeutics	4.2817 of 5 stars	$502.70 +1.1%	$646.00 +28.5%	+20.7%	$21.32B	$3.18B	17.99	1,400	Insider Trade
GMAB Genmab A/S	4.2675 of 5 stars	$32.65 +0.6%	$39.50 +21.0%	+23.9%	$20.25B	$4.13B	25.71	3,029	Analyst Revision
ASND Ascendis Pharma A/S	4.7241 of 5 stars	$264.92 +0.5%	$310.00 +17.0%	+18.7%	$16.44B	$814.57M	20.55	1,189	Analyst Downgrade
BBIO BridgeBio Pharma	3.582 of 5 stars	$72.38 -0.1%	$102.61 +41.8%	+24.9%	$14.16B	$713.07M	N/A	839	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTCT) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Competitors

PTCT vs. UTHR, GMAB, ASND, BBIO, and SMMT

How does PTC Therapeutics compare to United Therapeutics?

Summary

How does PTC Therapeutics compare to Genmab A/S?

Summary

How does PTC Therapeutics compare to Ascendis Pharma A/S?

Summary

How does PTC Therapeutics compare to BridgeBio Pharma?

Summary

How does PTC Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Competitors

PTCT vs. UTHR, GMAB, ASND, BBIO, and SMMT

How does PTC Therapeutics compare to United Therapeutics?

Which has stronger valuation and earnings, PTCT or UTHR?

Does the media favor PTCT or UTHR?

Do institutionals and insiders have more ownership in PTCT or UTHR?

Which has more volatility & risk, PTCT or UTHR?

Do analysts recommend PTCT or UTHR?

Is PTCT or UTHR more profitable?

Summary

How does PTC Therapeutics compare to Genmab A/S?

Do analysts rate PTCT or GMAB?

Is PTCT or GMAB more profitable?

Do institutionals & insiders hold more shares of PTCT or GMAB?

Does the media favor PTCT or GMAB?

Which has more risk and volatility, PTCT or GMAB?

Which has better valuation & earnings, PTCT or GMAB?

Summary

How does PTC Therapeutics compare to Ascendis Pharma A/S?

Is ASND or PTCT more profitable?

Which has more volatility and risk, ASND or PTCT?

Does the media favor ASND or PTCT?

Which has stronger valuation & earnings, ASND or PTCT?

Do analysts rate ASND or PTCT?

Summary

How does PTC Therapeutics compare to BridgeBio Pharma?

Do insiders & institutionals believe in PTCT or BBIO?

Is PTCT or BBIO more profitable?

Which has stronger earnings & valuation, PTCT or BBIO?

Does the media favor PTCT or BBIO?

Do analysts rate PTCT or BBIO?

Which has more risk and volatility, PTCT or BBIO?

Summary

How does PTC Therapeutics compare to Summit Therapeutics?

Does the media refer more to SMMT or PTCT?

Is SMMT or PTCT more profitable?

Do analysts prefer SMMT or PTCT?

Do institutionals and insiders have more ownership in SMMT or PTCT?

Which has higher valuation & earnings, SMMT or PTCT?

Which has more risk & volatility, SMMT or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools